Trial Profile
Double-blind, Randomized, Parallel-group, Dose Ranging, Multicenter Study to Evaluate the Efficacy and Safety of 2.5, 10, 35 and 50 mg AVE 7688 Once Daily, Using 100 mg Losartan-potassium Once Daily as Calibrator, for 12 Months Treatment, in Patients With Mild to Moderate Hypertension.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 03 Sep 2021
Price :
$35
*
At a glance
- Drugs Ilepatril (Primary) ; Losartan
- Indications Hypertension
- Focus Registrational; Therapeutic Use
- Acronyms RAVEL-1
- Sponsors Sanofi
- 28 Dec 2008 The number of trial centres changed from 22 to 22.
- 18 Dec 2008 Planned number of patients changed from 1730 to 1940 as reported by ClinicalTrials.gov.
- 25 Apr 2008 Status changed from in progress to completed, reported by ClinicalTrials.gov.